Fawzia Bardag to Boronic Acids
This is a "connection" page, showing publications Fawzia Bardag has written about Boronic Acids.
Connection Strength
1.908
-
Bortezomib enhances fatty liver preservation in Institut George Lopez-1 solution through adenosine monophosphate activated protein kinase and Akt/mTOR pathways. J Pharm Pharmacol. 2014 Jan; 66(1):62-72.
Score: 0.428
-
Proteasome inhibitor treatment in alcoholic liver disease. World J Gastroenterol. 2011 May 28; 17(20):2558-62.
Score: 0.363
-
Proteasome inhibitor up regulates liver antioxidative enzymes in rat model of alcoholic liver disease. Exp Mol Pathol. 2011 Feb; 90(1):123-30.
Score: 0.349
-
The proteasome inhibitor, PS-341, causes cytokeratin aggresome formation. Exp Mol Pathol. 2004 Feb; 76(1):9-16.
Score: 0.219
-
Ethanol withdrawal induced CYP2E1 degradation in vivo, blocked by proteasomal inhibitor PS-341. Free Radic Biol Med. 2002 Jan 01; 32(1):17-21.
Score: 0.189
-
Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury. Exp Mol Pathol. 2013 Apr; 94(2):352-9.
Score: 0.101
-
The use of a reversible proteasome inhibitor in a model of Reduced-Size Orthotopic Liver transplantation in rats. Exp Mol Pathol. 2012 Aug; 93(1):99-110.
Score: 0.096
-
Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis. Exp Mol Pathol. 2012 Aug; 93(1):26-34.
Score: 0.096
-
Proteasome inhibition induces cytokeratin accumulation in vivo. Exp Mol Pathol. 2004 Apr; 76(2):83-9.
Score: 0.055
-
Aggresome formation in liver cells in response to different toxic mechanisms: role of the ubiquitin-proteasome pathway and the frameshift mutant of ubiquitin. Exp Mol Pathol. 2001 Dec; 71(3):241-6.
Score: 0.012